ERBB2 and neoplasm: As an example from other tumor entities, we were able to demonstrate an adaptive response to EGFR inhibition or HER2 inhibition, leading to a rapid, compensatory counter-upregulation of the respective heterodimerization partner, HER2 or EGFR, respectively [40].